Chemical Nametaliglucerase alfa
Dosage FormInjection (intravenous; 200 units/vial)
Drug ClassEnzymes
CompanyPfizer Inc.
Approval Year2012


  • For the treatment of type 1 gaucher disease in patients 4 years and older with a confirmed diagnosis.
Last updated on 5/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Elelyso (taliglucerase alfa) Prescribing Information2012Pfizer Inc., New York, NY